EPZM
Epizyme, Inc.
NASDAQHealthcareBiotechnologyUS
Company Profile
CEO
Robert Bazemore
IPO Date
2013-05-31
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Epizyme, Inc.
CEO
Robert Bazemore
IPO Date
2013-05-31
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| -4.7 |
| 31 Dec 2019 | FY | 100.0% | -715.5% | -51.4% | -40.1% | 0.14 | 11.61 | -13.0 |
| 31 Dec 2018 | FY | 100.0% | -569.7% | -53.1% | -44.9% | 0.00 | 7.20 | -3.6 |
| 31 Dec 2017 | FY | 100.0% | -1343.1% | -57.1% | -46.4% | 0.00 | 11.59 | -5.7 |
| 31 Dec 2016 | FY | 100.0% | -1376.4% | -54.6% | -43.7% | 0.00 | 11.50 | -6.3 |
| 31 Dec 2015 | FY | 100.0% | -5170.9% | -78.1% | -60.7% | 0.01 | 11.55 | -4.8 |
| 31 Dec 2014 | FY | 100.0% | -132.8% | -34.3% | -27.6% | 0.00 | 11.44 | -11.3 |
| 31 Dec 2013 | FY | 100.0% | -5.1% | -3.3% | -2.1% | 0.00 | 4.62 | -101.8 |
| 31 Dec 2012 | FY | 100.0% | -1.6% | 1.4% | -0.7% | 0.00 | 2.83 | -702.4 |
| -0.7 |
| 31 Dec 2021 | Q4 | 72.8% | -437.3% | 244.8% | -17.5% | -11.56 | 4.56 | -1.3 |
| 30 Sept 2021 | Q3 | 61.6% | -1265.8% | -428.0% | -19.8% | 15.60 | 5.53 | -2.0 |
| 30 Jun 2021 | Q2 | 80.8% | -494.7% | -95.2% | -18.3% | 3.46 | 6.66 | -3.3 |
| 31 Mar 2021 | Q1 | 62.6% | -920.9% | -57.1% | -17.3% | 1.91 | 8.73 | -3.2 |
| 31 Dec 2020 | Q4 | 78.2% | -790.8% | -35.8% | -14.0% | 1.28 | 9.33 | -4.2 |
| 30 Sept 2020 | Q3 | 54.9% | -1572.4% | -22.9% | -14.7% | 0.37 | 8.95 | -5.4 |
| 30 Jun 2020 | Q2 | 58.6% | -2369.3% | -19.9% | -13.7% | 0.31 | 11.57 | -6.9 |
| 31 Mar 2020 | Q1 | 54.7% | -3762.0% | -15.0% | -11.3% | 0.21 | 14.80 | -7.6 |